Cargando…

Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors

BACKGROUND: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. METHODS: Twenty patients treated with meloxicam were followed up every...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Ja Young, Gupta, Sanjay, Cho, Hwan Seong, Park, Min Suk, Mok, Su Jung, Han, Ilkyu, Kim, Han-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Orthopaedic Association 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964272/
https://www.ncbi.nlm.nih.gov/pubmed/29854347
http://dx.doi.org/10.4055/cios.2018.10.2.225
_version_ 1783325153889878016
author Cho, Ja Young
Gupta, Sanjay
Cho, Hwan Seong
Park, Min Suk
Mok, Su Jung
Han, Ilkyu
Kim, Han-Soo
author_facet Cho, Ja Young
Gupta, Sanjay
Cho, Hwan Seong
Park, Min Suk
Mok, Su Jung
Han, Ilkyu
Kim, Han-Soo
author_sort Cho, Ja Young
collection PubMed
description BACKGROUND: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. METHODS: Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months. RESULTS: Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years. CONCLUSIONS: The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.
format Online
Article
Text
id pubmed-5964272
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Orthopaedic Association
record_format MEDLINE/PubMed
spelling pubmed-59642722018-06-01 Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors Cho, Ja Young Gupta, Sanjay Cho, Hwan Seong Park, Min Suk Mok, Su Jung Han, Ilkyu Kim, Han-Soo Clin Orthop Surg Original Article BACKGROUND: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. METHODS: Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months. RESULTS: Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years. CONCLUSIONS: The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor. The Korean Orthopaedic Association 2018-06 2018-05-18 /pmc/articles/PMC5964272/ /pubmed/29854347 http://dx.doi.org/10.4055/cios.2018.10.2.225 Text en Copyright © 2018 by The Korean Orthopaedic Association http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cho, Ja Young
Gupta, Sanjay
Cho, Hwan Seong
Park, Min Suk
Mok, Su Jung
Han, Ilkyu
Kim, Han-Soo
Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title_full Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title_fullStr Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title_full_unstemmed Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title_short Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors
title_sort role of nonsteroidal anti-inflammatory drug in treatment of extra-abdominal desmoid tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964272/
https://www.ncbi.nlm.nih.gov/pubmed/29854347
http://dx.doi.org/10.4055/cios.2018.10.2.225
work_keys_str_mv AT chojayoung roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT guptasanjay roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT chohwanseong roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT parkminsuk roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT moksujung roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT hanilkyu roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors
AT kimhansoo roleofnonsteroidalantiinflammatorydrugintreatmentofextraabdominaldesmoidtumors